Clinical Trial Update: Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients [Phase 1]

View source ↗

Summary

This is a Phase I/II feasibility trial evaluating Brentuximab Vedotin with second-line salvage DHAP chemotherapy in patients with refractory or relapsed Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)
• CISPLATIN (cisplatin)
• CYTARABINE (CYTARABINE)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Marjolein Spiering | Conditions: Hodgkin Lymphoma, Refractory | Phase 1 | Status: UNKNOWN